Incyte Q1 Earnings Call Highlights

2 hours ago 1

MarketBeat

Tue, April 28, 2026 astatine 9:17 AM CDT 9 min read

Incyte logo

Key Points

Strong commencement to 2026: Q1 gross roseate 21% to $1.27 cardinal and nett income were up 20% to $1.1 cardinal (Jakafi $758M), Incyte reaffirmed full‑year 2026 nett income guidance of $4.77–$4.94 billion portion investing much successful late‑stage programs, which lifted R&D and operating expenses.
Povorcitinib momentum: The FDA accepted the HS filing and 2 Phase III vitiligo trials (STOP‑V1/STOP‑V2) met superior endpoints with the 30 mg dose showing robust F‑VASI75 responses and a accordant 52‑week information profile, supporting a planned regulatory submission successful H1 2027.
Broader late‑stage pipeline and commercialized gains: Hematology/oncology income jumped 116% to $204M led by Niktimvo, Monjuvi and Zynyz, and Incyte is advancing pivotal Phase III programs including INCA033989 (mutant CALR) and KRAS G12D inhibitor INCB161734 successful first‑line PDAC.
Interested successful Incyte Corporation? Here are 5 stocks we similar better.

Can Incyte Deliver connected 447% EPS Forecasts and Pipeline Hype?

Incyte (NASDAQ:INCY) reported what absorption described arsenic a beardown commencement to 2026, driven by broad-based request crossed its commercialized portfolio and continued advancement of aggregate late-stage pipeline programs. During the company’s first-quarter net call, executives highlighted 20% year-over-year nett income growth, regulatory advancement for povorcitinib successful hidradenitis suppurativa (HS), and recently announced affirmative signifier III results for povorcitinib successful nonsegmental vitiligo.

First-quarter results amusement wide portfolio maturation

Chief Executive Officer Bill Meury said first-quarter full gross roseate 21% year-over-year to $1.27 billion, portion nett income accrued 20% to $1.1 billion. “Sales accrued for each marketed product, some successful the U.S. and internationally, and was driven by beardown medicine and measurement request crossed the portfolio,” Meury said.

→ Pipelines and Automation: 2 Energy Plays Built for Any Oil Price

5 apical healthcare stocks for net maturation successful 2024

Jakafi first-quarter income were $758 million, up 7% year-over-year. Meury said medicine request accrued 6% with “broad-based maturation crossed each indications, MF, PV, and GVHD,” adding that caller diligent starts remained beardown and formulary sum remained broad. Incyte anticipates support and motorboat of Jakafi XR successful the mediate of the year, and Meury said the institution estimates the extended-release merchandise could scope 10% to 30% of Jakafi’s concern by 2029.

Excluding Jakafi, Meury said Incyte’s “core business” grew 63% year-over-year, supported by contributions crossed hematology, oncology, and immunology. Opzelura income totaled $143 million, up 20% from the anterior year, including $106 cardinal successful the U.S. (up 12%) and $37 cardinal internationally (up 56%). Meury said underlying U.S. medicine request for Opzelura roseate 17% year-over-year. He reiterated that Opzelura remains nether reappraisal successful Europe for mean atopic dermatitis, with support and motorboat expected successful the 2nd fractional of 2026.

Read Entire Article